A. Lianne Messchendorp

Author

University Medical Center Groningen ORCID

Also Known As

A Lianne Messchendorp, A Messchendorp, A. Lianne Messchendorp, A. L. Messchendorp, A. Lianne Messchendorp, A. Lianne Messchendorp, Lianne Messchendorp, Messchendorp, A.L.

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen Radboud University Nijmegen Radboud University Medical Center University of Amsterdam

About

A. Lianne Messchendorp is an author at University Medical Center Groningen specializing in medicine, chronic kidney disease, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	381
2	Public Health	1	1	15
3	Biostatistics	1	1	41
4	Epidemiology	1	1	15
5	Global Health	1	1	15

A. Lianne Messchendorp

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant Jan‐Stephan Sanders, Fréderike J. Bemelman, A. Lianne Messchendorp, Transplantation	2021	189
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International Roman‐Ulrich Müller, A. Lianne Messchendorp, Henrik Birn, Nephrology Dialysis Transplantation HypertensionPatient SelectionRenal PathologyGenetic EpidemiologyRenal Inflammation	2021	122
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Jan‐Stephan Sanders, Fréderike J. Bemelman, A. Lianne Messchendorp, PubMed	2022	121
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease Esther Meijer, Folkert W. Visser, R. Aerts, JAMA	2018	102
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease R. Aerts, Wietske Kievit, Hedwig M. A. D‘Agnolo, Gastroenterology UrologyHepatologyMedicineLiver PhysiologyGenetics	2019	82
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial Marcia M. L. Kho, A. Lianne Messchendorp, Sophie C. Frölke, The Lancet Infectious Diseases VaccinologyVaccinationTransplantationVaccine DevelopmentKidney Transplant	2022	68
Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice Xiaochen Chen, Jin Ma, Tony Kwan, Scientific Reports	2018	56
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant Marcia M. L. Kho, Marlies E. J. Reinders, Carla C. Baan, Nephrology Dialysis Transplantation	2021	55
Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors A. Lianne Messchendorp, Esther Meijer, Folkert W. Visser, American Journal of Nephrology Glomerular DiseaseRenal PathologyGenetic EpidemiologyImmunologyPathology	2019	53
Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant Jan‐Stephan Sanders, A. Lianne Messchendorp, Rory D. de Vries, Clinical Infectious Diseases	2022	52

Page 1